 ERYTECH Pharma Nasdaq Euronext: ERYP, a clinical-stage biopharmaceutical company developing red blood cell-based cancer therapeutics, today provided an update on the pivotal Phase 3 clinical trial for advanced metastatic pancreatic cancer TRYbeCA-1, which is evaluating the efficacy and safety of ERYTECHs lead product candidate eryaspase in combination with chemotherapy as second-line therapy. We are pleased that the TRYbeCA-1 trial has continued to progress well despite the challenges caused by the COVID-19 global pandemic, said Gil Beyen, CEO of ERYTECH. 